EP1613732A4 - Complexes intracellulaires utilises comme biomarqueurs - Google Patents

Complexes intracellulaires utilises comme biomarqueurs

Info

Publication number
EP1613732A4
EP1613732A4 EP20040758577 EP04758577A EP1613732A4 EP 1613732 A4 EP1613732 A4 EP 1613732A4 EP 20040758577 EP20040758577 EP 20040758577 EP 04758577 A EP04758577 A EP 04758577A EP 1613732 A4 EP1613732 A4 EP 1613732A4
Authority
EP
European Patent Office
Prior art keywords
biomarkers
intracellular complexes
intracellular
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20040758577
Other languages
German (de)
English (en)
Other versions
EP1613732A2 (fr
Inventor
Sharat Singh
M Youssouf Badal
Xuenguang Jin
Hossein Salimi-Moosavi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Monogram Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/623,057 external-priority patent/US7105308B2/en
Application filed by Monogram Biosciences Inc filed Critical Monogram Biosciences Inc
Publication of EP1613732A2 publication Critical patent/EP1613732A2/fr
Publication of EP1613732A4 publication Critical patent/EP1613732A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20040758577 2003-04-01 2004-03-30 Complexes intracellulaires utilises comme biomarqueurs Withdrawn EP1613732A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45988803P 2003-04-01 2003-04-01
US10/623,057 US7105308B2 (en) 2002-07-25 2003-07-17 Detecting receptor oligomerization
US49448203P 2003-08-11 2003-08-11
US50803403P 2003-10-01 2003-10-01
US51294103P 2003-10-20 2003-10-20
US52325803P 2003-11-18 2003-11-18
PCT/US2004/009805 WO2004087887A2 (fr) 2003-04-01 2004-03-30 Complexes intracellulaires utilises comme biomarqueurs

Publications (2)

Publication Number Publication Date
EP1613732A2 EP1613732A2 (fr) 2006-01-11
EP1613732A4 true EP1613732A4 (fr) 2012-03-14

Family

ID=33136354

Family Applications (3)

Application Number Title Priority Date Filing Date
EP20040758577 Withdrawn EP1613732A4 (fr) 2003-04-01 2004-03-30 Complexes intracellulaires utilises comme biomarqueurs
EP04759064.1A Expired - Lifetime EP1613205B1 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface erbb utilises comme biomarqueurs
EP04759065A Withdrawn EP1613961A4 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface utilises comme biomarqueurs

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP04759064.1A Expired - Lifetime EP1613205B1 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface erbb utilises comme biomarqueurs
EP04759065A Withdrawn EP1613961A4 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface utilises comme biomarqueurs

Country Status (6)

Country Link
EP (3) EP1613732A4 (fr)
JP (2) JP2006523314A (fr)
AU (3) AU2004225439A1 (fr)
BR (3) BRPI0408961A (fr)
CA (3) CA2521077A1 (fr)
WO (3) WO2004092353A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
CA2521077A1 (fr) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Complexes de recepteurs de surface erbb utilises comme biomarqueurs
WO2005019470A2 (fr) 2003-08-11 2005-03-03 Monogram Biosciences, Inc. Detection et profilage de complexes moleculaires
EP1681983A4 (fr) * 2003-10-14 2008-12-10 Monogram Biosciences Inc Analyse de la voie de signalisation de la tyrosine kinase de recepteur pour diagnostic et therapie
EP1805676A1 (fr) * 2004-09-22 2007-07-11 Tripath Imaging, Inc. Procedes et produits logiciels pour l'analyse et l'optimisation de marqueurs candidats pour le pronostic du cancer
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2008102A4 (fr) * 2006-04-18 2009-07-08 Wellstat Biologics Corp Detection de proteines dans des cellules neoplastiques en circulation
CA2663595A1 (fr) * 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Schemas proteomiques de pronostic du cancer et signatures predictives
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
JP5656406B2 (ja) 2006-11-28 2015-01-21 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツングＵ３ Ｐｈａｒｍａ ＧｍｂＨ 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
ES2526211T3 (es) * 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
CA2711843C (fr) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Procedes de diagnostic du her-2
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
US8168755B2 (en) * 2008-05-07 2012-05-01 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of Bcl-2 family and uses thereof
UA104868C2 (uk) * 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
SG172984A1 (en) * 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
AU2010229924B2 (en) 2009-03-24 2016-07-21 Plus Therapeutics Inc. Devices and methods of cell capture and analysis
JP5718319B2 (ja) 2009-05-14 2015-05-13 ネステク ソシエテ アノニム Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
MX358013B (es) 2009-11-13 2018-08-01 Amgen Inc Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
CA2792327C (fr) 2010-03-11 2019-09-24 Merrimack Pharmaceuticals, Inc. Utilisation d'inhibiteurs d'erbb3 dans le traitement de cancers du sein triples negatifs et de type basal
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
US20140248291A1 (en) * 2011-03-30 2014-09-04 The Uab Research Foundation Modulation of Cellular Migration
JP6186575B2 (ja) * 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
US20150150869A1 (en) 2012-06-20 2015-06-04 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2922544B1 (fr) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Méthodes et compositions utiles dans le traitement de maladies faisant appel à des protéines de la famille bcl-2 avec des dérivés de quinoléine
WO2014165855A1 (fr) * 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systèmes et procédés pour faciliter le diagnostic, le pronostic et le traitement d'un cancer sur la base de la détection de l'activation de her3
WO2014188363A1 (fr) * 2013-05-21 2014-11-27 Nestec S.A. Procédés pour prédire et améliorer la survie de patients atteints d'un cancer colorectal
WO2015017788A1 (fr) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Méthode permettant de prédire la sensibilité d'un cancer
WO2015066305A1 (fr) 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Procédés de détermination de la chimiosensibilité et de la chimiotoxicité
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
US20190041389A1 (en) * 2015-02-13 2019-02-07 The University Of Queensland Methods for classifying tumors and uses therefor
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN108780089B (zh) 2016-03-15 2020-09-08 美国控股实验室公司 评估细胞间的蛋白质相互作用的方法
US20200355694A1 (en) * 2017-11-20 2020-11-12 Konica Minolta, Inc. Drug Evaluation Method
IT201800008274A1 (it) * 2018-08-31 2020-03-02 Alifax Srl Metodo immunometrico per analisi cliniche biologiche

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024205A1 (fr) * 1994-03-07 1995-09-14 New York University Medical Center Procede et compositions de traitement du cancer du sein
WO2003068808A1 (fr) * 2002-02-13 2003-08-21 Garvan Institute Of Medical Research Nouveaux complexes proteiques et utilisations associees
WO2003076649A1 (fr) * 2002-03-05 2003-09-18 Aclara Biosciences, Inc. Analyse multiplex au moyen de sensibilisateurs fixes a une membrane
WO2004091384A2 (fr) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Complexes de recepteurs de surface erbb utilises comme biomarqueurs
WO2005037071A2 (fr) * 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Analyse de la voie de signalisation de la tyrosine kinase de recepteur pour diagnostic et therapie

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ATE162892T1 (de) 1992-07-31 1998-02-15 Behringwerke Ag Photoaktivierbare chemiluminizierende matrices
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5693271A (en) 1994-09-01 1997-12-02 Chase Industries, Inc. Rotationally molding an insulated plastic molded door with integral hinge
US5599631A (en) 1995-03-08 1997-02-04 Eastman Kodak Company Fluorinated elastomer/fluorinated resin compositions for toner fusing members
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6095661A (en) 1998-03-19 2000-08-01 Ppt Vision, Inc. Method and apparatus for an L.E.D. flashlight
US6316603B1 (en) * 1998-09-08 2001-11-13 Agouron Pharmaceuticals, Inc. Modifications of the VEGF receptor-2 protein and methods of use
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6627400B1 (en) * 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6346384B1 (en) 2000-03-27 2002-02-12 Dade Behring Inc. Real-time monitoring of PCR using LOCI
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
WO2001084157A2 (fr) 2000-05-04 2001-11-08 Dade Behring Marburg Gmbh Compositions servant a la detection d'analytes multiples
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
US20020127654A1 (en) * 2001-02-22 2002-09-12 Price Virginia L. Compositions and methods for production cell culture
PL373962A1 (en) 2001-05-21 2005-09-19 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
WO2003006947A2 (fr) 2001-07-09 2003-01-23 Aclara Biosciences, Inc. Methode et composition de criblage cellulaire
CA2354690A1 (fr) 2001-07-20 2001-10-27 Jan Prinzmetal Tapis
US6545102B1 (en) * 2001-09-27 2003-04-08 Lumigen, Inc. Polymer-supported photosensitizers
CA2477953A1 (fr) * 2002-03-01 2003-09-12 Roger Williams Hospital Compositions et procedes se rapportant a la proteine shc pour le pronostic de cancer du sein, de la prostate et de l'ovaire
ES2392525T3 (es) * 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
JP4443407B2 (ja) * 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024205A1 (fr) * 1994-03-07 1995-09-14 New York University Medical Center Procede et compositions de traitement du cancer du sein
WO2003068808A1 (fr) * 2002-02-13 2003-08-21 Garvan Institute Of Medical Research Nouveaux complexes proteiques et utilisations associees
WO2003076649A1 (fr) * 2002-03-05 2003-09-18 Aclara Biosciences, Inc. Analyse multiplex au moyen de sensibilisateurs fixes a une membrane
WO2004091384A2 (fr) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Complexes de recepteurs de surface erbb utilises comme biomarqueurs
WO2005037071A2 (fr) * 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Analyse de la voie de signalisation de la tyrosine kinase de recepteur pour diagnostic et therapie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004087887A2 *
SHINODA SACHIKO ET AL: "Interaction of 14-3-3 with Bid during seizure-induced neuronal death.", JOURNAL OF NEUROCHEMISTRY, vol. 86, no. 2, July 2003 (2003-07-01), pages 460 - 469, XP002667074, ISSN: 0022-3042 *
ZHA J ET AL: "Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL", CELL, CELL PRESS, US, vol. 87, 15 November 1996 (1996-11-15), pages 619 - 628, XP002110634, ISSN: 0092-8674, DOI: 10.1016/S0092-8674(00)81382-3 *

Also Published As

Publication number Publication date
WO2004092353A2 (fr) 2004-10-28
AU2004230700A1 (en) 2004-10-28
AU2004225439A1 (en) 2004-10-14
EP1613205A4 (fr) 2006-11-29
CA2521106A1 (fr) 2004-10-14
BRPI0408961A (pt) 2006-10-31
BRPI0408928A (pt) 2006-09-12
WO2004091384A2 (fr) 2004-10-28
EP1613732A2 (fr) 2006-01-11
CA2521077A1 (fr) 2004-10-28
CA2521082A1 (fr) 2004-10-28
WO2004087887A2 (fr) 2004-10-14
EP1613205A2 (fr) 2006-01-11
JP2006523314A (ja) 2006-10-12
WO2004087887A3 (fr) 2006-06-15
AU2004229348A1 (en) 2004-10-28
WO2004092353A3 (fr) 2005-03-03
EP1613961A2 (fr) 2006-01-11
EP1613205B1 (fr) 2013-04-24
JP2006521821A (ja) 2006-09-28
BRPI0408950A (pt) 2006-03-28
WO2004091384A3 (fr) 2005-12-29
EP1613961A4 (fr) 2007-03-07

Similar Documents

Publication Publication Date Title
EP1613732A4 (fr) Complexes intracellulaires utilises comme biomarqueurs
NL300885I2 (nl) Irinotecansucrosofaatzout
DE602004001908D1 (de) Kompressor
ATE453394T1 (de) Multipartikeln
EP1901702A4 (fr) Complexes ioniques
LU92427I2 (fr) Aripiprazole
IS8108A (is) Ný efnasambönd
DE502004003964D1 (de) Metallkomplexe
DK1581535T5 (da) Pyrrolopyridazinderivater
DE602004005498D1 (de) Fluoreffiziente appreturen für textilien
DE602004000230D1 (de) Verdichter
DE602004000334D1 (de) Kompressor
IS8228A (is) Ný asetídínefnasambönd
EP1703127A4 (fr) Compresseur
DE602004031650D1 (de) Drehbund für hubsäge
DE602004010443D1 (de) Kompressor
IS8292A (is) Ný efnasambönd
EP1640609A4 (fr) Compresseur
DE602004022063D1 (de) Mehrzweckschlitten
EP1650439A4 (fr) Compresseur
ITRM20040204A1 (it) Compressore alternativo.
FI20035051A0 (fi) Hakun vastaterä
FI5853U1 (fi) Vaappu
DE112004002154D2 (de) Faltschachtel
SE0303452D0 (sv) New compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051026

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20060817BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120210

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/53 20060101AFI20120203BHEP

Ipc: G01N 33/574 20060101ALI20120203BHEP

Ipc: G01N 33/542 20060101ALI20120203BHEP

17Q First examination report despatched

Effective date: 20150326

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171003